In this episode of SurgOnc Today, Julie Hallet, MD, MSc, Vice-Chair of the SSO HPB disease site working group, and Lavanya Yohanathan, MD, from the HPB disease site working group are joined by Melissa Hogg, MD, from Northshore University Hospital and Giovanni Marchegiani, MD, from the University of Padova. They will discuss two key clinical scenarios during surveillance of pancreatic cystic neoplasms: when to pull the trigger on resection and if or when to discontinue surveillance. Show notes:  - Next generation sequencing of pancreatic cyst fluid: https://pubmed.ncbi.nlm.nih.gov/36209796/ - Discontinuation of surveillance for selected IPMNs: https://pubmed.ncbi.nlm.nih.gov/37406887/ - iCyst app: https://apps.apple.com/us/app/icyst/id1479833485 

In this episode of SurgOnc Today, Alexander Parikh MD, MPH, FACS, FSSO, will continue the discussion on the nuts and bolts of neoadjuvant therapy for pancreas cancer with Syed Ahmad, MD, and Susan Tsai, MD, MHS. In part 2, they specifically discuss two important aspects of delivering neoadjuvant therapy for pancreatic adenocarcinoma. Specifically, how to choose which specific regimens to use and the role of chemoradiation. 

In this episode of SurgOnc Today®, Genevieve Boland, MD, PhD, Amanda Kirane, MD, and G. Paul Wright, MD, discuss breaking news and updates from the Society of Immunotherapy of Cancer (SITC) and Society of Melanoma Research (SMR) meetings.

In this episode of SurgOnc Today®, Puneet Singh, MD, and Anna Weiss, MD, discuss the newly published SOUND and LUMINA clinical trials. Both trials explore local regional de-escalation, omitting sentinel lymph node biopsy and radiation, respectively. They discuss the treatment challenges that incorporating these trial results may pose with their special guest, Kimberly Corbin, MD.

In this episode of SurgOnc Today®, Samantha Ruff, MD, Rupen Shah, MD, Mustafa Raoof, MD, and Danielle DePeralta, MD, discuss the role of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) and its emerging role in the management of peritoneal surface malignancies. We review the existing literature for this treatment modality and the recently published multi-center phase I trial performed in the United States. 

In this episode of SurgOnc Today®, Mihir M. Shah, MD, Mashaal Dhir, MD, and June S. Peng, MD, discuss the workup and management of gastric adenocarcinoma. The discussion elaborates on several scenarios, including molecular testing, surgical approaches to advanced gastric cancers, treatment sequencing, tumor-related gastric obstruction management, diagnostic laparoscopy role, perioperative management, and low-volume carcinomatosis management.

In this episode of SurgOnc Today®, Michail Mavros, MD, and Sonia T. Orcutt, MD from the University of Arkansas for Medical Sciences are joined by Jonathan R. Strosberg, MD, head of the Neuroendocrine Division in the Department of Gastrointestinal Oncology, Moffitt Cancer Center and Past President of the North American Neuroendocrine Tumor Society (NANETS), and Mary A. Maluccio, MD, MPH, chief of the Division of Surgical Oncology at LSU and medical director of the NET Louisiana program. Gastric NETs are often misunderstood neoplasms with recent updates in classification and management, and the panelists discuss the most up-to-date information on how to diagnose and manage gastric NETs.

This episode of SurgOnc Today®, features guest faculty, Astrid Botty Van Den Bruele, MD, and Meghan Flanagan, MD, MPH. In a contemporary group of patients diagnosed with contralateral axillary metastases (CAM), those selected for treatment with presumed curative intent experienced improved OS when compared to stage IV (M1) patients. The current literature, as well as some forthcoming data, adds additional support for re-evaluating the stage IV designation, in favor of N3, and consideration of curative intent treatment in this disease entity.

Historically, mastectomy was recommended for women with multiple ipsilateral breast cancer due to perceptions regarding high rates of local recurrence with breast conservation. A recent prospective clinical trial demonstrated that breast conservation therapy may be appropriate to consider for women with multiple ipsilateral breast cancer. This episode of SurgOnc Today® features Ashley Woodfin, MD, discussing with Judy C. Boughey, MD, and Kari Rosenkranz, MD, the findings of the Alliance Z11102 clinical trial and how to implement these into practice.

In patients with invasive breast cancer presenting with node positive disease, neoadjuvant chemotherapy is often recommended and can result in surgical downstaging in a significant proportion of cases. Management of the axilla in this setting has evolved. For those found to have a nodal pathologic complete response (ypN0), an axillary lymph node dissection (ALND) can potentially be avoided. Astrid Botty van den Bruele, MD, FACS, and Giacomo Montagna, MD, MPH, discuss the newly presented OPBC-04/EUBREAST-06 study, which supports omission of ALND in this population. The axillary staging techniques (SLNB vs TAD) are also addressed.

On SurgOnc Today®, Jeffrey J. Pelton, MD, and Randall P. Scheri, MD, discuss the use and efficiency of four-dimensional CT scanning in preoperatively localizing adenomas in patients with primary hyperparathyroidism prior to cervical exploration. The discussion includes: The anatomic body planes and the “fourth dimension” of CT scanning. How the 4D CT scan is performed and how this achieves localization of abnormal parathyroid glands. The role 4D CT scanning plays in the pre-operative work-up for primary hyperparathyroidism. What the surgeon wants to know from the radiologist on a 4D CT report. Potential risks and pitfalls in interpreting a 4D CT scan prior to proceeding with surgical exploration. Dr. Pelton and Dr. Scheri also discuss what the literature has reported on this subject, how they approach surgical exploration using the information and their own experiences with this test.

This session will review state of the art therapy for peritoneal mesothelioma. The discussion includes cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as well as systemic chemotherapy and immunotherapy. Edward Levine, MD, moderates this podcast and is Professor of Surgery and Chief, Surgical Oncology at Wake Forest University. Trang Nguyen, MD, is an Assistant Professor of Surgery at Indiana University and Sinziana Dumitra, MD, MSc, FRCSC, FSSO, is an Assistant Professor of Surgery at McGill University. 

This episode of SurgOnc Today® features Tina Hieken, MD, from Mayo Clinic, in Rochester, MN, and Chair of the SSO Melanoma Disease Site Work Group interviews John Hyngstrom, MD, from the University of Utah and Michael Lowe, MD, MA, from Emory University. They will review recently reported phase II melanoma neoadjuvant studies and how the findings from these trials are important to surgical oncologists specializing in melanoma.

During this episode of SurgOnc Today®, Austin D. Williams, MD, Fox Chase Cancer Center, Zachary J. Brown, DO, New York University - Long Island School of Medicine, and Allison Martin, MD, University of Texas MD Anderson Cancer Center, discuss the various career options within surgical oncology, including breast, hepatobiliary and colorectal. The discussion covers information specific to each of these surgical oncology subspecialties and provides information important for any trainee who is contemplating a career as a surgical oncologist.

On SurgOnc Today®, J. Joshua Smith, MD, PhD, Glen Balch, MD, and Christina Bailey, MD, discuss modern rectal cancer trials and their relevance to clinical practice.

In this episode of SurgOnc Today, Alexander Parikh MD, MPH, FACS, FSSO, from the University of Texas, San Antonio and Chair of the SSO HPB Disease Site Work Group, and Julie Hallet, MD, M.Sc., FRCSC, from the University of Toronto, and Vice-Chair of the SSO HPB Disease Site Work Group, are joined by Flavio G. Rocha, MD, FACS, FSSO, from the Oregon Health and Science University and Susanne G. Warner, MD, from the Mayo Clinic Rochester. They discuss two important aspects of delivering neoadjuvant therapy for pancreatic adenocarcinoma: the use of staging laparoscopy and the assessment of response. 

In this episode of SurgOnc Today, Genevieve Boland, MD, PhD, FSSO, of Massachusetts General Hospital – Vice Chair of the SSO Melanoma Disease Site Working Group is joined by fellow committee members, Rogerio Neves, MD, PhD, FACS, FSSO, from Moffitt Cancer Center and Amanda Kirane, MD, FACS, FSSO, from Stanford University. They discuss the current clinical application of tumor infiltrating lymphocytes (TILs) in melanoma, recent clinical trial results, advances in TILs production that have allowed for expanded patient access, and insight on appropriate patient or tumor selection for therapy.

In this episode of SurgOnc Today®, Chantal Reyna MD, Medical Director of Breast and Chief of Breast Surgery in the Upland, PA is joined by Jennifer Plichta MD, Associate Professor of Surgery at Duke University in Durham, NC and Chandler Cortina MD, Assistant Professor of Surgery and Chief of the Surgical Oncology Breast & Endocrine Service at the Medical College of Wisconsin at Medical College of Wisconsin in Milwaukee, WI. With the treatment of female breast cancer continuously evolving, the treatment of male breast cancer can be a challenge due to its rarity. This episode focuses on the current incidence, evaluation, and management of male breast cancer.

Desmoids are a unique subset of soft tissue tumors. While they can cause symptoms related to local progression, they do not metastasize and a subset have indolent behavior, in some cases regressing spontaneously. Because surgery for desmoids can be morbid and recurrence rates are high, non-operative treatment has become the preferred treatment strategy for desmoid patients. Active observation, regional therapies for anatomically appropriate cases and medical therapies can all be employed in patients with desmoid-type fibromatosis. Aimee M. Crago, MD, PhD, and Brian E. Kadera, MD, discuss cases requiring non-operative management to assist listeners in integrating recently published data into their practices.

In this episode of Surg Onc Today, Kimberly Washington, MD, Hepato-Pancreato-Biliary Surgeon at Texas Health Surgical Specialist/Texas Christian University in Fort Worth, Texas is joined by Jennifer Tseng MD, Medical Director of Breast Surgery, City of Hope Orange County, Associate Clinical Professor, Department of Surgery and Brian Sparkman, MD, MS, FACS, Complex General Surgical Oncology Fellow at Virginia Commonwealth University Medical Center, Richmond, VA. The initial year of practice can be a challenging yet pivotal learning experience. The episode offers expert advice, insider insights, and personal anecdotes to help ease your transition. Tune in for practical guidance that can assist you during this critical time.

In this episode of SurgOnc Today®, Doreen Agnese, MD, from The Ohio State University Medical Center is joined by Toan Nguyen, MD, from Lakeland Regional Health and Mark Robson, MD, from Memorial Sloan Kettering Cancer Center. Realizing that genetic testing is being performed more frequently and by many different providers for patients both with and without breast cancer, they discuss the management of non-BRCA breast cancer susceptibility genes.

In this episode of SurgOnc Today®, Mio Kitano, MD, MS, FACS, FSSO, Surgical Oncologist at UT Health San Antonio, TX, is joined by Mashaal Dhir, MD, FACS, FSSO, Surgical Oncologist and Section Chief of HPB Surgery at The SUNY Upstate Medical University in Syracuse, NY, and Nathan Bahary, MD, PhD, Division Chief of Medical Oncology at the Allegheny Health Network Cancer Institute and Director of AHNCI Clinical Research in Pittsburgh, PA. They discuss the most up-to-date information on how to diagnose and manage small bowel NET. Moderator:  Mio Kitano, MD, MS, FACS, FSSO - UT Health San Antonio Faculty:   Mashaal Dhir, MD, FACS, FSSO - SUNY Upstate Medical University Nathan Bahary, MD, PhD - Allegheny Health Network

On SurgOnc Today®, Patrick S. Sullivan, MD, Maria Diab, MD, and Nader Hanna, MD, discuss the use of liquid biopsy or ctDNA to identify molecular disease prior to clinically detectable disease. Molecular detection of ctDNA can be used to detect minimal residual disease (MRD) which is residual cancer cells detected only by molecular techniques but not by conventional testing. Molecular testing of ctDNA can also be used to detect molecular relapse. This allows the molecular detection of occult disease during adjuvant therapy or during surveillance. This information can be prognostic and help determine patients with increased risk of recurrent disease who may benefit from adjuvant therapy and targeted chemotherapy. It can also be used for prediction for adjuvant chemotherapy. In addition it can be used for de-escalation of chemotherapy by identifying patients who would not gain the benefit of chemotherapy. There are 2 approaches for detecting MRD. One is tumor agnostic and the second is tumor informed. The tumor informed has higher sensitivity by identifying mutations in the tumor tissue and tracking these mutations in the plasma.

In this episode of SurgOnc Today®, Dr. Julie Hallet from the University of Toronto, and Vice-Chair of the SSO HPB disease site working group, is joinded by Dr. James R. Howe from the University of Iowa and Dr. Nadine Mallak from the Oregon Health and Science University. They discuss how somatostatin receptor PET imaging, such as DOTATE-PET, can be used to guide and support the surgical management of pancreatic neuroendocrine tumors. Moderator: Julie Hallet MD, Msc; Associate Professor of Surgery. University of Toronto, Toronto, Canada; Surgical Oncologist, Susan Leslie Clinic for Neuroendocrine Tumors – Sunnybrook Health Sciences Centre, Toronto, Canada Vice-Chair, HPB DSWG, SSO Faculty:  James R. Howe, MD Professor of Surgery and Director of Surgical Oncology and Endocrine Surgery, Roy J. and Lucille A. Carver University of Iowa College of Medicine, Iowa City, Iowa Nadine Mallak, MD Associate Professor, Department of Diagnostic Radiology, Nuclear Medicine and Body Imaging sections Director, PET/MRI, Clinical, Oregon Health and Science University, Portland, OR   References NANETS guidelines for the surgical management of pancreatic neuroendocrine tumors https://nanets.net/images/guidelines/2020_NANETS_Consensus_Paper_on_the_Surgical_Management_of_Pancreatic_Neuroendocrine_Tumors.pdf   SNMMI appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors https://s3.amazonaws.com/rdcms-snmmi/files/production/public/Quality/jnm202275_New%20-%20revised.pdf

During this episode of SurgOnc Today®, Valerie P. Grignol, MD, Vice Chair of the SSO Sarcoma Disease Site Work Group, Timur Mitin, MD, PhD, Arun Singh, MD, and Neha Goel, MD, discuss the evaluation, treatment and management of primary and radiation induced angiosarcoma of the breast through a case based discussion.

In this episode of SurgOnc Today®,  Judy Boughey, MD, from the Mayo Clinic in Rochester, MN, and Vice Chair of the SSO Breast Disease Site Work Group, discusses with her colleagues how they manage a missing clipped axillary lymph node. She is joined by Puneet Singh, MD, from MD Anderson Cancer Center and Firas Eladoumikdachi, MD, from Rutgers Cancer Institute of New Jersey. Their discussion is focused on patients with node positive breast cancer who were treated with neoadjuvant chemotherapy.

In this episode of SurgOnc Today®, Laurence McCahill, MD, of Western Michigan University is joined by Julie Barone, DO, Medical Director of Vail Comprehensive Breast Care and John Abad, MD, of Northwestern Medicine Regional Medical Group.  They discuss their personal pathways that brought them into leadership roles within the community care practice setting, including their experiences with the accreditation of their programs, the establishment of their research programs and the use of their programs’ outcomes.  They also touch upon the characteristics that a physician seeking a career at a satellite program of an academic medical center should seek out and they address their recommendations for achieving balance between their administrative and surgery roles.

In this episode of SurgOnc Today®, Martin Goodman, MD, is joined by fellow members of the SSO Peritoneal Surface Malignancy Disease Site Workgroup, Ioannis Konstantinidis, MD, FACS, FSSO, and Trang Nguyen, MD.  They discuss various scenarios in which patients present with malignant bowel obstruction, reviewing the decision making process and treatment options to meet the individualized needs of each patient.  

In this episode of SurgOnc Today®, Tina Hieken, MD, Jeffrey Farma, MD, and Danielle Bello, MD, discuss the evolving role of surgery in the contemporary management of patients with Stage IV melanoma. The discussion includes the changing role of surgery for patients with metastatic melanoma in the current landscape of efficacious systemic immunotherapies and targeted therapies, and the role of surgical oncologists in  clinical trials testing new and expanded approaches such as adoptive T cell therapy for patients with advanced melanoma.

In this episode of SurgOnc Today®, Evan Glazer, MD, PhD, FACS, Chair of the SSO Gastrointestinal Disease Site Work Group, is joined by panelists to provide an International Perspective on GI Malignancies.  Their discussion focuses on the challenges and opportunities for professional collaboration and patient care as it relates to esophageal and gastric malignancies. Panelists include:  Eduardo A. Guzmán Huerta, MD, Professor in Surgery, Tecnológico de Monterrey, Nuevo león, Mexico Nia Zalamea, MD, FACS, Assistant Professor General Surgery, Director UTHSC Global Surgery Institute, The University of Tennessee Health Science Center, Memphis, TN  Alejandro Rodriguez, MD – Assistant Professor, Tecnológico de Monterrey, Nuevo león, Mexico 

During this episode of SurgOnc Today®, Heather Wachtel, MD, University of Pennsylvania, Mahsa Javid, MD, MA, PhD, Medical University of South Carolina, Colleen Kiernan, MD, MPH, FACS, Vanderbilt University, and Cord Sturgeon, MD, Northwestern University, discuss strategies for building an early surgical practice with an endocrine focus. Many of these strategies will be relevant to complex general surgical oncology and breast careers. The discussion covers components of practice building including clinical resources, establishing a referral basis, mentoring and support, and promotion. References/Resources Tips and Tricks for Finding a Job (SurgOnc Today 2022) Surgical Oncologists in the Community Cancer Care Setting: Opportunities for Graduating Fellows (SurgOnc Today 2021)

In part two of the series on the role of transplant for liver tumors, Alexander Parikh, MD, MPH, Chair of the SSO HPB Disease Site Work Group, is again joined by Ana Luiza Gleisner, MD, PhD, from the University of Colorado Anschutz Medical Campus in Aurora, CO and Shimul A. Shah, MD, MHCM, from the University of Cincinnati College of Medicine in Cincinnati, OH. They review the role of liver transplantation for malignancies of and to the liver. The discussion also covers the role of liver transplantation in the treatment of colorectal liver metastases including the impact of liver-directed therapies on the role of liver transplant.

During this episode of SurgOnc Today, Alexander Parikh, MD, MPH, Chair of the SSO HPB DSWG, is joined by Ana Luiza Gleisner, MD, PhD, from the University of Colorado Anschutz Medical Campus in Aurora, CO and Shimul A. Shah, MD, MHCM, from the University of Cincinnati College of Medicine in Cincinnati, OH. They review the role of liver transplantation for malignancies of and to the liver. In this first installment of the two-part series, they discuss the role of liver transplantation in the treatment of primary hepatobiliary malignancies including hepatocellular cancer and cholangiocarcinoma.

In this episode of SurgOnc Today®, Olga Kantor, MD, Brigham and Women's Hospital, Boston, MA, Emily Sturm, MD, Southern Illinois University School of Medicine, Springfield, IL, Ibrahim Nassour, MD, University of Florida Health, Gainesville, FL, and Kimberly Washington, MD, FACS, Oregon Health and Science University, Portland, OR, discuss tips and tricks for fellows navigating the process of finding a job. They discuss how to prepare while in fellowship, how to find jobs, and how to approach interviews and negotiations. References Guetter CR, McGuire KP, Oropallo AR, et al. Surgical job negotiations: How current literature and expert opinion can inform your strategies. Am J Surgery. 2020 June 25;220(2020):1201-7. The Graduating Surgeon: A Primer for Surgical Trainees. Young Fellows Association, American College of Surgeons, downloaded 18 Jan 2022. https://www.facs.org/-/media/files/member-services/yfa/yfa_graduating_surgeon_primer.ashx

In this episode of SurgOnc Today®, David Bartlett, MD, Chair of the Allegheny Health Network Cancer Institute and SSO Past-President, is joined by Margo Shoup, MD, MBA, President of the Orlando Health Cancer Institute and Glenda Callender, MD, Medical Director of Endocrine Surgery at the Hartford HealthCare Cancer Institute. They discuss their experiences with mid-career transitions from academia to the community cancer care setting.

In this episode of SurgOnc Today, Tina Hieken, MD, from the Mayo Clinc, in Rochester, MN interviews Georgia Beasley, MD, MHS, from Duke University in Durham, NC and Christina Stevenson, MD, MS, from the University of Connecticut in Farmington, CT. They review the following studies and how their findings are important to surgical oncologists specializing in melanoma. Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) LBA3_PR - Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma

During this episode of SurgOnc Today, Dr. Alexander Parikh, Vice Chair of the SSO HPB DSWG, is joined by Dr. Flavio Rocha from the Oregon Health & Science University in Portland, OR and Dr. Sepideh Gholami from the UC Davis Medical Center in Sacramento, CA. They review the findings and status of non-therapeutic HPB trials including the use of perioperative steroids for liver resection and pancreatic cyst surveillance.

During this episode of SurgOnc Today®, Kenneth Cardona, MD, Nicholas Tawa, MD, PhD, Elizabeth Davis, MD, and Marwan Moussa, MD, discuss the value and role of cryoablation in the management of patients with desmoid tumors and examine clinical scenarios in which this treatment modality should be offered. They also discuss the CRYODESMO-1 prospective trial which investigated the utility of cryoablation in desmoid tumors.

In this episode of SurgOnc Today®,  Dr. Jennifer Plichta is joined by Dr. Ann Partridge and Dr. Kristin Rojas to discuss practical pearls for addressing women’s sexual health concerns during breast cancer treatment and prevention using case-based discussions to illustrate common scenarios that breast surgeons may encounter in their clinic. These may include managing sexual health concerns in the neoadjuvant and adjuvant setting, as well as how to approach symptom management for patients seen in a high-risk program. Jennifer Plichta, MD, MS is an Associate Professor of Surgery at Duke University Ann Partridge, MD, MPH is a Professor of Medicine at Harvard Medical School, and Vice Chair of Medical Oncology at Dana-Farber Cancer Institute Kristin Rojas, MD is an Assistant Professor of Surgery at the University of Miami, Sylvester Comprehensive Cancer Center  References: ASCO Guideline: Carter J, Lacchetti C, Anderson B, et al. Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. Journal of Clinical Oncology 2018 36:5, 492-511https://ascopubs.org/doi/full/10.1200/JCO.2017.75.8995 ACOG Supports Use of Vaginal Estrogen in Breast Cancer Survivors: https://www.acog.org/news/news-releases/2016/02/acog-supports-the-use-of-estrogen-for-breast-cancer-survivors Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003 Mar;6(1):45-52. PMID: 12725664. Le Ray I, Dell'Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012 Sep;135(2):603-9. doi: 10.1007/s10549-012-2198-y. Epub 2012 Aug 19. PMID: 22903687.https://link.springer.com/article/10.1007%2Fs10549-012-2198-y Studies on Risk of Recurrence With Vaginal Estrogen:  American Association of Sexuality Educators, Counselors, and Therapists (AASECT): https://www.aasect.org/ PROSE Study: Rebbeck TR, Friebel T, Wagner T, et a. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 1;23(31):7804-10. doi:10.1200/JCO.2004.00.8151. Epub 2005 Oct 11. PMID: 16219936.

In this episode of SurgOnc Today®,  Dr. Judy Boughey, from the Mayo Clinic, in Rochester, MN and Dr. Carlos Garcia-Etienne, from the Ospedale Santa Chiara in the Autonomous Province of Trento, Italy review three practice changing studies and how their findings are important to breast surgical oncologists. During the podcast, they will review: Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial (JAMA Oncol. 2020 Jan 1;6(1):75-82. doi: 10.1001/jamaoncol.2019.4320.) Pembrolizumab for Early Triple-Negative Breast Cancer (N Engl J Med 2020; 382:810-821 DOI: 10.1056/NEJMoa1910549.) Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer (N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215.)

In this episode of SurgOnc Today®, Emily Sturm MD, Malini D. Sur, MD, and James Nitzkorski, MD, discuss what graduating fellows will want to contemplate when considering becoming a community-based surgical oncologist. They also review the variety of practice settings, the types of available support you’ll want to examine, and some of the day-to-day opportunities and challenges to expect.

During this episode of SurgOnc Today, Jan Franko, MD, PhD, Niraj J. Gusani, MD, MS, and Viet H. Le, MD, discuss malignant bowel obstruction (MBO). They define MBO broadly as any symptoms compatible with bowel obstruction in settings of rather large volume intraabdominal malignancy. Some 30% GI cancers, and some 50% ovarian cancers develop MBO – often a preterminal event. For clarity, they did not consider clinically more straightforward situations of malignant single-point obstructions treatable by resection, bypass or stent. They will forego localized gastric outlet, duodenal and rectosigmoid primary tumors. They explore what symptom burden could be potentially qualify as obstructive symptoms: frank MBO with total dependency on gastric decompression, or perhaps symptoms of progressive weight loss without over need for gastric decompression or parenteral nutrition. Over past 20 years median overall survival those diagnosed with MBO is 3-4 months. If operated, perioperative 30-day mortality is commonly 6-15%, and perhaps as high as 40% among those with ascites. These outcomes are drive by difficult-to-treat disease and palliative nature of therapy. Depressing outcomes are difficult to explain to patients, families, and administrators. Care for those suffering. Treatment options include non-operative (gastric decompression, antiemetics, somatostatin analogies, TPN/IVF support, and hospice care), non-operative interventional (GI stenting), and operative (resections, bypass, stoma, functional palliative cytoreduction, ascites control). They discuss expectations from accrued SWOG S1316 trial: Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction.

In this episode of SurgOnc Today®, members of the SSO Fellows and Young Attendings Subcommittee, including Emily Sturm, MD, Zhi Ven Fong, MD, MPH, Allison Martin, MD, and Olga Kantor, MD, review common questions about preparing for and navigating the application process of surgical oncology fellowships. To view the article referenced in the podcast, please click here.

In this episode of SurgOnc Today®, Antonio Picon, MD, Director of Surgical Oncology at Stamford Health and his guest Steven McClane, MD, from Cooper Health will discuss the National Accreditation Program for Rectal Cancer and how surgeons can apply, develop and maintain a rectal cancer center of excellence. Learn about the process to become accredited and take your rectal cancer program to a different level. https://www.facs.org/quality-programs/cancer/naprc

During this episode of SurgOnc Today, Richard White, MD, Chair of the SSO Melanoma Disease Site Work Group and Giorgos Karakousis, MD, explore the science behind gene expression profiling and its role in patients with early stage melanoma. Richard White, MD, Chief, Division of Surgical Oncology, , endowed professor of surgery, co-director of the Barbara Levine Breast Center and co-director of the Cutaneous Malignancy Program at Atrium Health Levine Cancer Institute. Giorgos Karakousis, MD - Associate Professor of Surgery at the Hospital of the University of Pennsylvania.

In this episode Carmen Solorzano, MD, Chair of the SSO Endocrine Disease Site Work Group, Electron Kebebew, MD, and Geoffrey Young, MD, PhD, discuss two practice changing studies regarding the management of Medullary and Anaplastic Thyroid Cancer. Carmen Solorzano, MD, Professor of Surgery, Chair, Department of Surgery, and Director, Vanderbilt Endocrine Surgery Geoffrey Young, MD, PhD, Chief, Head and Neck Surgery; Miami Cancer Institute Electron Kebebew, MD, Professor and Chief, Stanford University School of Medicine References/Resources 1-Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. Wirth LJ et al. N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651.PMID: 32846061 2- 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer- American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force. KC Bible, E Kebebew et al. Thyroid Published Online:12 March 2021https://doi.org/10.1089/thy.2020.0944 3-Nihilism no more: The 2021 ATA Anaplastic Thyroid Cancer Guidelines. JD Pasternak, TE Angell, J Lorch. Clinical Thyroidology Vol. 33, No.5. Published Online:7 May 2021https://doi.org/10.1089/ct.2021;33.229-234

Recent trials in sarcoma sought to determine the impact of neoadjuvant therapies and histologic/genomically specific treatments. Valerie Grignol, MD, Gabriel R. Tinoco Suarez, MD, and Alessandro Gronchi, MD, FSSO, discuss the following recent trials will. The EORTC-62902:STRASS trial evaluated the impact of neoadjuvant radiotherapy for retroperitoneal sarcoma on abdominal recurrence-free survival. A study by the Italian, Spanish, French and Polish Sarcoma groups sought to determine if histology-tailored neoadjuvant chemotherapy was superior to standard anthracycline plus ifosfamide for high-risk extremity and trunk soft tissue sarcoma for disease-free and overall survival. The NAVIGATOR study evaluated the PDGFRA inhibitor avapritinib and its activity in D842V-mutant gastrointestinal stromal tumors. Lastly the INVICTUS study evaluated the impact of further line therapy ripretinib, a switch-control tyrosine kinase inhibitor, on progression-free survival in advanced gastrointestinal stromal tumors. Valerie Grignol, MD - Member, SSO Sarcoma Disease Site Work Group, Assistant Professor of Surgery, The Ohio State University Gabriel R. Tinoco Suarez, MD - Medical Oncologist and Clinical Assistant Professor - Division of Medical Oncology at The Ohio State University Alessandro Gronchi, MD, FSSO - Chair Sarcoma Service - Department of Surgery; Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy)

In this episode, Peritoneal Surface Malignancy Disease Site Workgroup Member, Beth Helmink, MD, PhD, from Washington University in St. Louis, reviews recent data regarding the evolving role of HIPEC in Ovarian Cancer.  Joining her for this discussion are two renowned gynecologic oncologists specializing the treatment of ovarian cancer, Willemien van Driel, MD, Netherlands Cancer Institute, and Ernst Lengyel, MD, PhD, University of Chicago.

In this episode, Karyn Stitzenberg, MD, MPH, Vice Chair of the SSO Colorectal Disease Site Work Group is joined by Patrick S. Sullivan, MD, FACS, FASCRS, Associate Professor of Surgery and Chief Quality Officer, Division of Colorectal Surgery at the Winship Cancer Institute of Emory University in Atlanta, Georgia. They review practice changing studies in colorectal surgical oncology from 2020.

In this episode of SurgOnc Today™, Evan Glazer, MD, PhD, FACS, FSSO, Vice Chair of the SSO Gastrointestinal Disease Site Workgroup, is joined by Julie Hallet MD, MSc, FRCSC, Natalie Coburn MD, MPH and Jesse Zuckerman, MDCM, all from the University of Toronto. Focusing on 2020 Practice Changing Studies in Gastrointestinal Surgical Oncology, they review the Declining Use of Red Blood Cell Transfusions for Gastrointestinal Cancer Surgery: A Population-Based Analysis. Ann Surg Oncol 28, 29–38 (2021). https://doi.org/10.1245/s10434-020-09291-y

In this episode, Melissa Hogg, MD from Northshore University Health System, chair of the Hepato-Pancreato-Biliary Disease Site Workgroup, is joined by Jashodeep Datta, MD, from the University of Miami School of Medicine in Miami, FL and Dr. Carrie Luu, MD, from Saint Louis University Hospital in St. Louis, MO.  They review practice changing studies in Hepato-Pancreato-Biliary Surgical Oncology from 2020. They discuss the SWOG S1505 clinical trial manuscript and the Know Your Tumor Registry publication.

In this episode, Ko Un “Clara” Park, MD, FACS, Member of the SSO Breast DSWG and Assistant Professor of Surgery at The Ohio State University Wexner Medical Center reviews wire-free alternatives for localization of non-palpable breast lesions for surgery. Panelists and alternatives reviewed include: Dr. Michael Alvarado, Professor of Surgery and member of the breast care and melanoma programs at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the use of radioactive seed. Dr. Susan Hoover, Professor of Surgery at the Moffitt Cancer Center in Tampa, Florida, reviews other ‘seed-like’ localizers such as Savi Scout, Magseed, and the Faxitron localizer. Dr. Lee G. Wilke, the Hendricks endowed chair in Breast Cancer Research; a tenured Professor of Surgery and the Associate Director for Clinical Research for the University of Wisconsin Carbone Cancer Center as well as the Director of the UW Health Breast Center in Madison, WI, discusses an innovative intraoperative navigation platform for tumor identification, a Smart Clip technology which can be inserted at time of the biopsy.

Anthony Yang, MD, MS, FACS, Chair of the SSO Endocrine Disease Site Work Group is joined by fellow Workgroup Members, Mark Cohen, MD, FACS, FSSO and Cord Sturgeon, MD, MS, FACS, along with Samuel Hyde, CGC. This episode is the first of a two-part series.  The expert panel will discuss the incidence, prevalence, and epidemiology of primary hyperparathyroidism (PHPT).  They will review inherited syndromes associated with PHPT as well as when to send patients/families to genetic counseling for further evaluation and how to diagnose those syndromes.  Part two of our series will focus on the surgical management of hereditary forms of PHPT. Dr. Cohen is Professor of Surgery, Pharmacology and Biomedical Engineering; Vice Chair in Surgery for Clinical Operations; Director of the Center for Surgical Innovation; Director of the Medical School Pathway of Excellence in Innovation and Entrepreneurship; and Director of Endocrine Surgery Research at the University of Michigan. Dr. Sturgeon is Professor of Surgery, Chief of Endocrine Surgery at the Robert H. Lurie Comprehensive Cancer Center and the Director of Surgery at Northwestern Memorial Hospital.  Samuel Hyde is an ABGC-certified genetic counselor who specializes in hereditary cancer and is an instructor at the Northwestern University Feinberg School of Medicine.

Anthony Yang, MD, MS, FACS, Chair of the SSO Endocrine Disease Site Work Group is joined by fellow Workgroup Members, Mark Cohen, MD, FACS, FSSO and Cord Sturgeon, MD, MS, FACS, along with Samuel Hyde, CGC. This podcast is the second of a two-part series.  Whereas the first episode discussed an overview of primary hyperparathyroidism (PHPT) and the inherited syndromes associated with it, this episode will focus on the surgical management of hereditary forms of PHPT, specifically multiple endocrine neoplasia syndromes types 1 & 2 (MEN1 & MEN2). Dr. Cohen is Professor of Surgery, Pharmacology and Biomedical Engineering; Vice Chair in Surgery for Clinical Operations; Director of the Center for Surgical Innovation; Director of the Medical School Pathway of Excellence in Innovation and Entrepreneurship; and Director of Endocrine Surgery Research at the University of Michigan. Dr. Sturgeon is Professor of Surgery, Chief of Endocrine Surgery at the Robert H. Lurie Comprehensive Cancer Center and the Director of Surgery at Northwestern Memorial Hospital.  Samuel Hyde is an ABGC-certified genetic counselor who specializes in hereditary cancer and is an instructor at the Northwestern University Feinberg School of Medicine.

In this episode of SurgOnc Today®, Richard White, MD, Chair of the SSO Melanoma Disease Site Work Group, moderates as Melanoma DSWG members, Nasreen Vohra, MD reviews updates on local therapies and Michael Lowe, MD, MA, reviews updates on neoadjuvant trials in melanoma.

In this episode, Edward Levine, MD Chair of the SSO Peritoneal Surface Malignancy DSWG, is joined by Brian Badgwell, MD of MD Anderson Cancer Center and Pieter Tanis, MD, PhD of the University of Amsterdam.  They discuss whether patients at high risk of peritoneal dissemination from gastric and colon cancers should undergo HIPEC as an adjuvant therapy. 

Unplanned surgical excisions of soft tissue sarcomas (“whoops operations”) can complicate the subsequent multidisciplinary management of the primary tumor due to potential microscopic tumor seeding of prior surgical sites, violation of uninvolved anatomic compartments, and sometimes a lack of gross residual tumor on staging imaging. Valerie Grignol, MD and Kilian Salerno, MD join John M. Kane III, MD, Vice-Chair of the SSO Sarcoma Disease Site Work Group, to discuss how unplanned excisions might alter the surgical and radiation decision-making for the treatment of soft tissue sarcomas.

The 2020 Commission on Cancer (CoC) accreditation standards introduced six new operative standards pertaining to the technical aspects of cancer surgery. In this episode, SSO Colorectal Disease Site Work Group Chair, David Shibata, MD, James Fleshman, MD, and David Dietz, MD, describe Standard 5.7, Total Mesorectal Excision (TME) for Rectal Cancer and will cover the details of the standard, the key steps of TME, and its’ supporting evidence.

Timothy Mullett, MD, Stephen Swisher, MD, and Nirmal Veeramachaneni, MD discuss the Commission on Cancer (CoC) Standard 5.8 including a review of the requirements for nodal assessment during curative operation for lung cancer and best practices to accomplish the requirement.

In part two of the HPB Incidentalomas episode, Alexander A. Parikh, MD, Vice Chair of the Hepato-Pancreato-Biliary Disease Site Work Group and disease site work group members Jin He, MD, PhD, and H.J. Kim, MD discuss the incidence, workup, treatment options, and controversies in the management of benign and indolent incidental lesions involving the duodenum and pancreas.

In this episode, Sandra L. Wong, MD, MS, FSSO, speaks with Ryan Fields, MD, recipient of the 2014 SSO Clinical Investigator Award, about the impact the award had in helping him to achieve his future career goals. 

Sean Dineen, MD, Laura Lambert, MD, and Chukwuemeka Ihemelandu, MD, discuss the state of the art management of colorectal cancer metastatic to the peritoneum including natural history and treatment options. They also preview future directions for the field.

In this episode of SurgOnc Today®, Carla Fisher, MD, Amy Degnim, MD and Faina Naklis, MD, discuss the management of high risk breast lesions including radial scars, papillomas without atypia, atypical ductal hyperplasia, atypical lobular hyperplasia and lobular carcinoma in situ. Carla Fisher, MD, is a member of the SSO Breast DSWG and Director of Breast Surgery at Indiana University, Amy Degnim, MD, is the Joe M. and Ruth Roberts Professor of Surgery and Co-Leader of the Women’s Cancer Program at the Mayo Clinic and Faina Naklis, MD, is a surgeon at Brigham and Women’s / Dana-Farber.

In this episode, Sandra Wong, MD, speaks with Ronald DeMatteo, MD, about the opportunities that stemmed from receiving the 2008 SSO Clinical Investigator Award. Dr. DeMatteo shares his perspective on how the CIA award came at a critical time and helped to facilitate publication of the research.

In this episode, Sandra Wong, MD, speaks with Ronald DeMatteo, MD, about the SSO Research and Education Fund’s “Honor Your Mentor” campaign. Dr. DeMatteo talks about his mentors, Leslie Blumgart, MD, and Murray Brennan, MD.

In this episode, Sandra Wong, MD, speaks with Tari King, MD, about the opportunities that stemmed from receiving the 2009 SSO Clinical Investigator Award. Dr. King shares her perspective on how to advance research and leadership career goals.

Vadim Gushchin, MD, Brian Badgwell, MD, and Jeremy Davis, MD discuss the role and timing of preoperative treatments before cytoreduction and HIPEC for gastric cancer. The panelists offer useful tips on surgical management of gastric cancer patients with peritoneal carcinomatoses, such as how to decide on the extent of the surgery, whether patients with CDH1 mutation should be treated differently, and others.

In this episode of SurgOnc Today™, Brian Badgwell, MD, Farshid Dayyani MD, PhD, and Maheswari Senthil, MD, discuss the management of gastric cancer peritoneal carcinomatosis. Evaluation of response to systemic treatment, use of intraperitoneal chemotherapy and nuances of patient selection for Cytoreductive surgery are discussed.

In this episode, SSO President James Howe, MD, SSO Secretary Kelly Hunt, MD, and Matthew Katz, MD, discuss ACS Commission on Cancer accreditation standards 5.3 through 5.8, what these standards are, where they came from, and why they are so important to all surgeons and their patients.

In this episode of SurgOnc Today™, Benjamin Golas, MD, Mio Kitano, MD and Laleh Melstrom, MD, from the SSO Gastrointestinal Disease Site Work Group provide an overview of the current data regarding the multimodal approach to the diagnosis and management of Gastrointestinal Stromal Tumors.  

In this episode of SurgOnc Today™, Gastrointestinal Disease Site Work Group Chair, Vance Sohn, MD, discusses PRRT with SSO President, James Howe, MD and Thomas Clancy, MD from the Gastrointestinal Disease Site Work Group. They discuss the current indications, efficacy, and what the future holds for PRRT.

In this episode, Melissa Hogg, MD, Chair of the Hepato-Pancreato-Biliary Disease Site Work Group and disease site work group members Jin He, MD, PhD, and H.J. Kim, MD, discuss the common and mostly benign imaging findings of the liver and biliary system with a focus on indications for surveillance, surgery, or additional necessary work-up.  

The recently published EORTC 62092 trial (STRASS) examines abdominal recurrence in patients after surgical resection of retroperitoneal sarcomas.  This randomized study compared these recurrences in patients receiving neoadjuvant radiation versus those undergoing surgery alone.  Rebecca Gladdy MD, PhD and Ashleigh Guadagnolo, MD join moderator and SSO Sarcoma Disease Site Work Group Chair, Aimee Crago, MD, PhD, to provide insight and analysis from both surgical and radiation oncology perspectives, discussing how this practice-changing trial is altering the approach to patients with these diseases. 

Kandace McGuire, MD, Chair of the SSO Breast Disease Site Work Group, moderates as Breast DSWG member Jennifer Plichta, MD, MS, presents practice changing studies from 2019.

Alexander Parikh, MD, MPH, Vice Chair of the SSO Hepato-Pancreato-Biliary Disease Site Work Group moderates as Marcus Tan, MD, presents practice changing studies from 2019.

Tina J. Hieken, MD, Vice Chair of the SSO Melanoma Disease Site Work Group, moderates as Melanoma DSWG members, Jessica Cintolo-Gonzalez, MD, and Kelly Olino, MD, present practice changing studies from 2019.

Anthony Yang, MD, MS, Chair, and Carmen Solorzano, MD, Vice-Chair of the SSO Endocrine Disease Site Work Group, moderate as Linwah Yip, MD, from the Endocrine DSWG presents the following practice-changing studies in endocrine surgical oncology from 2019. Executive Summary of the American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Patel KN, Yip L, Lubitz CC, Grubbs EG, Miller BS, Shen W, Angelos P, Chen H, Doherty GM, Fahey TJ 3rd, Kebebew E, Livolsi VA, Perrier ND, Sipos JA, Sosa JA, Steward D, Tufano RP, McHenry CR, Carty SE.  Ann Surg. 2020 Mar;271(3):399-410. PMID: 32079828 Thyroid Lobectomy for T1b-T2 Papillary Thyroid Cancer with High-Risk Features. Suman P, Razdan SN, Wang CE, Tulchinsky M, Ahmed L, Prinz RA, Winchester DJ. J Am Coll Surg. 2020 Jan;230(1):136-144. PMID: 31672668 Five-Year Results of Radiofrequency and Laser Ablation of Benign Thyroid Nodules: A Multicenter Study from the Italian Minimally Invasive Treatments of the Thyroid Group. Bernardi S, Giudici F, Cesareo R, Antonelli G, Cavallaro M, Deandrea M, Giusti M, Mormile A, Negro R, Palermo A, Papini E, Pasqualini V, Raggiunti B, Rossi D, Sconfienza LM, Solbiati L, Spiezia S, Tina D, Vera L, Stacul F, Mauri G. Thyroid. 2020 Jul 24. PMID: 32578498 Clinical Presentation, Treatment, and Outcome of Parathyroid Carcinoma: Results of the NEKAR Retrospective International Multicenter Study. Lenschow C, Schrägle S, Kircher S, Lorenz K, Machens A, Dralle H, Riss P, Scheuba C, Pfestroff A, Spitzweg C, Zielke A, Nießen A, Dotzenrath C, Riemann B, Quinkler M, Vorländer C, Zahn A, Raue F, Chiapponi C, Iwen KA, Steinmüller T, Kroiss M, Schlegel N; NEKAR study group. Ann Surg. 2020 Jul 7. PMID: 32649472 Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. Assié G, Jouinot A, Fassnacht M, Libé R, Garinet S, Jacob L, Hamzaoui N, Neou M, Sakat J, de La Villéon B, Perlemoine K, Ragazzon B, Sibony M, Tissier F, Gaujoux S, Dousset B, Sbiera S, Ronchi CL, Kroiss M, Korpershoek E, De Krijger R, Waldmann J, Quinkler M, Haissaguerre M, Tabarin A, Chabre O, Luconi M, Mannelli M, Groussin L, Bertagna X, Baudin E, Amar L, Coste J, Beuschlein F, Bertherat J.JAMA Oncol. 2019 Jul 11;5(10). PMID: 31294750 

Lesly Dossett, MD interviews Dan Boffa, MD about his work exploring the rationale and potential advantages of cancer networks, while also reviewing the data on patient perceptions and surgical quality within cancer networks. 

Join moderator Vance Sohn, MD and his guests Sarah DeSnyder, MD and Ching-Wei Tzeng, MD from the MD Anderson Cancer Center as they resume their conversation on opioid optimization. These experts will discuss lessons learned in advancing post-operative pain management as well as practical tips on how to implement optimization pathways.

Join moderator Vance Sohn, MD and his guests Sarah DeSnyder, MD and Ching-Wei Tzeng, MD from the MD Anderson Cancer Center as they discuss the important role that surgical oncologists play in post-operative opioid optimization.  Learn about innovative ways being implemented in the outpatient and inpatient settings that are leading to safer, patient-centered, post-operative pain management.  

SSO Secretary, Kelly Hunt, MD interviews Mehra Golshan, MD, and Eleftherios (Terry) Mamounas, MD, about their involvement with the manuscript, “COVID-19 Pandemic Breast Cancer Consortium’s Considerations for Re-Entry.” Dr. Golshan and Dr. Mamounas were appointed as SSO representatives to a consortium consisting of experts from The American Society of Breast Surgeons, the National Accreditation Program for Breast Centers, the National Comprehensive Cancer Network, the American College of Surgeons Commission on Cancer, the American College of Radiology and the American Society of Clinical Oncology.

SSO President, James Howe, MD, interviews George Chang, MD, MD Anderson Cancer Center, about his experience being diagnosed with and recovering from COVID-19. Dr. Howe and Dr. Chang discussed symptoms, testing, his hospitalization, returning to work and Dr. Chang’s experience donating his plasma to help give others passive immunity.

In this episode of SurgOnc Today™, Armando Giuliano, MD, Tari King, MD and Melissa Pilewskie, MD, discuss the management of the axilla after preoperative systemic therapy. Evaluation of the axilla pre- and post chemotherapy along with surgical management is discussed in a case with a 3 cm, poorly differentiated invasive ductal carcinoma.

In this episode of SurgOnc Today™, Armando Giuliano, MD, Tari King, MD and Otto Metzger, MD, discuss the choice between preoperative endocrine therapy and preoperative chemotherapy in hormone receptor positive breast cancer patients. Evaluation and treatment is discussed for a post-menopausal woman presenting a 3.4 cm node negative, invasive ductal carcinoma

In this episode of SurgOnc Today, Ajay Maker, MD, Director of Surgical Oncology at AIMMC/Creticos Cancer Center at the University of Illinois at Chicago, interviews SSO Gastrointestinal Disease Site Work Group members about the most influential papers in GI surgical oncology from 2019. Four conversations cover topics including: A recent Lancet study about combination chemotherapy for pancreatic cancer Advanced gastric cancer and perioperative chemotherapy regimens New therapies for metastatic gastric cancer An Annals of Surgical Oncology paper about diagnosing GI cancers from circulating tumor DNA Ajay Maker, MD, is the Director of Surgical Oncology at AIMMC/Creticos Cancer Center, and Associate Professor in the Department of Surgery, Division of Surgical Oncology at the University of Illinois at Chicago Evan S. Glazer, MD, PhD, is Assistant Professor of Surgery  and Principal Investigator, Center for Cancer Research at the University of Tennessee Health Science Center Yanghee Woo, MD, is Director, Gastroenterology Minimally Invasive Therapy Program and Associate Clinical Professor, Division of Surgical Oncology, Department of Surgery at City of Hope Mio Kitano, MD, is Assistant Professor in the Division of Surgical Oncology and Endocrine Surgery at the University of Texas Health San Antonio Carlos Chan, MD, PhD, is Assistant Professor of Surgery, Director-Molecular Epidemiology Resource Core, Assistant Professor of Radiation Oncology, Assistant Professor of Surgery, Surgical Oncology and Endocrine Surgery at the University of Iowa

SSO President-Elect, James R. Howe, MD, speaks with SSO Breast Cancer Disease Site Work Group Vice Chair, Kandace P. McGuire, MD. Dr. McGuire is the Chief, Section of Breast Surgery at the Massey Cancer Center at Virginia Commonwealth University, Richmond, VA.

SSO President-Elect, James R. Howe, MD provides various perspectives on endocrine cancers and COVID-19. Dr. Howe is the Director, Surgical Oncology and Endocrine Surgery at the Roy J. and Lucille A. Carver University of Iowa College of Medicine, Iowa City, IA.

SSO President, David L. Bartlett, MD speaks with SSO Colorectal Disease Site Work Group Chair, George J. Chang, MD, MS. Dr. Chang is the Deputy Department Chair, Department of Surgical Oncology, Division of Surgery, Chief, Section of Colon and Rectal Surgery at The University of Texas MD Anderson Cancer Center, Houston, TX.

SSO President, David L. Bartlett, MD speaks with SSO HPB Disease Site Work Group Vice Chair, Melissa E. Hogg, MD, MS. Dr. Hogg is the Director of HPB Surgery, Director of Robotic Training for Grainger Labs and Northshore University Healthsystem, Evanston, IL.

SSO President-Elect, James R. Howe, MD provides speaks with SSO Melanoma Disease Site Work Group Chair, Giorgos C. Karakousis, MD. Dr. Karakousis is an Associate Professor of Surgery at the Abramson Cancer Center University of Pennsylvania, Philadelphia, PA.

SSO President, David L. Bartlett, MD, speaks with SSO Peritoneal Surface Malignancy Disease Site Work Group Chair, Kiran K. Turaga, MD, MPH and SSO Sarcoma Disease Site Work Group Vice Chair, Aimee M. Crago, MD, PhD. Dr. Turaga is the Vice Chief, Section of General Surgery and Surgical Oncology (Strategy and Finance), Director, Surgical GI Cancer Program, Director, Regional Therapeutics Program at the University of Chicago Medicine, Chicago, IL. Dr. Crago is a Surgical Oncologist at Memorial Sloan Kettering Cancer Center, New York, NY.